NCT00819052 - Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients | Biotech Hunter

Enrollment

445

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

HIV Infections

Interventions

DRUG

Nevirapine XR

DRUG

Nevirapine XR

Nevirapine extended release

DRUG

Nevirapine IR

Nevirapine Immediate Release

Trial Locations (39)

Unknown

1100.1526.1012 Boehringer Ingelheim Investigational Site, Beverly Hills

1100.1526.1014 Boehringer Ingelheim Investigational Site, Beverly Hills

1100.1526.1011 Boehringer Ingelheim Investigational Site, Long Beach

1100.1526.1013 Boehringer Ingelheim Investigational Site, Los Angeles

1100.1526.1001 Boehringer Ingelheim Investigational Site, Washington D.C.

1100.1526.1004 Boehringer Ingelheim Investigational Site, Washington D.C.

1100.1526.1006 Boehringer Ingelheim Investigational Site, Clearwater

1100.1526.1002 Boehringer Ingelheim Investigational Site, Miami

1100.1526.1005 Boehringer Ingelheim Investigational Site, Miami Beach

1100.1526.1003 Boehringer Ingelheim Investigational Site, Berkley

1100.1526.1007 Boehringer Ingelheim Investigational Site, Austin

1100.1526.3306A Boehringer Ingelheim Investigational Site, Bobigny

1100.1526.3311A Boehringer Ingelheim Investigational Site, Bordeaux

1100.1526.3307A Boehringer Ingelheim Investigational Site, La Roche-sur-Yon

1100.1526.3312A Boehringer Ingelheim Investigational Site, Le Kremlin-Bicêtre

1100.1526.3301A Boehringer Ingelheim Investigational Site, Lyon

1100.1526.3310A Boehringer Ingelheim Investigational Site, Marseille

1100.1526.3308A Boehringer Ingelheim Investigational Site, Montpellier

1100.1526.3302A Boehringer Ingelheim Investigational Site, Nantes

1100.1526.3304A Boehringer Ingelheim Investigational Site, Nice

1100.1526.4902 Boehringer Ingelheim Investigational Site, Berlin

1100.1526.4903 Boehringer Ingelheim Investigational Site, Berlin

1100.1526.4904 Boehringer Ingelheim Investigational Site, Bochum

1100.1526.4905 Boehringer Ingelheim Investigational Site, Bonn

1100.1526.4907 Boehringer Ingelheim Investigational Site, Cologne

1100.1526.4914 Boehringer Ingelheim Investigational Site, Cologne

1100.1526.4906 Boehringer Ingelheim Investigational Site, Düsseldorf

1100.1526.4909 Boehringer Ingelheim Investigational Site, Frankfurt

1100.1526.4908 Boehringer Ingelheim Investigational Site, Frankfurt am Main

1100.1526.4901 Boehringer Ingelheim Investigational Site, Freiburg im Breisgau

1100.1526.4910 Boehringer Ingelheim Investigational Site, Hamburg

1100.1526.4911 Boehringer Ingelheim Investigational Site, Hamburg

1100.1526.4912 Boehringer Ingelheim Investigational Site, Hamburg

1100.1526.4913 Boehringer Ingelheim Investigational Site, Hanover

1100.1526.4915 Boehringer Ingelheim Investigational Site, München

1100.1526.4403 Boehringer Ingelheim Investigational Site, London

1100.1526.4405 Boehringer Ingelheim Investigational Site, London

1100.1526.4404 Boehringer Ingelheim Investigational Site, Manchester

1100.1526.4402 Boehringer Ingelheim Investigational Site, Tooting, London